(TCRT) Alaunos Therapeutics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TCRT) Alaunos Therapeutics, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Alaunos Therapeutics, Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing strategy, distribution channels, and promotional tactics to show how it competes in biotech/therapeutics. The page includes a real preview/sample of the analysis so you can assess style and content; purchase the full version to receive the complete ready-to-use report.
Product
TCR Library, 10 receptors
Alaunos Therapeutics, Inc.’s core product is its TCR Library platform, which includes 10 T-cell receptors in clinical development for adoptive T-cell receptor engineered therapies. As of July 2026, it is the company’s main product asset and targets solid tumors with shared cancer mutations. The program is built to broaden treatment options in cancers where shared mutations can support a wider patient fit.
Phase I/II clinical stage
Alaunos Therapeutics, Inc. lead product is still in Phase I/II, so it is not a marketed therapy yet. The value proposition rests on early safety and efficacy signals, not sales, and the mix is still research-led rather than revenue-led. Commercial launch depends on clear clinical benefit, later-stage success, and FDA progress, with no approved product or product sales today.
KRAS, TP53, EGFR targets
Alaunos Therapeutics, Inc.’s library targets mutated KRAS, TP53, and EGFR, three drivers found across hard-to-treat tumors; KRAS mutations appear in about 25% of solid tumors, while TP53 is altered in roughly 50%. EGFR mutations are common in non-small cell lung cancer, at about 10% to 15% in Western patients. This patient-matched design makes the offer highly specialized and precision-oncology focused.
Solid tumors, 6 cancer types
Alaunos Therapeutics, Inc. positions Solid tumors, 6 cancer types as a multi-cancer therapeutic platform for non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers, all large solid-tumor markets with high unmet need. The six-indication reach gives it more than one development path, which can matter in a market where one program can fail fast.
The company’s broad setup supports a platform story, not a single-asset pitch.
- 6 target cancer types
- Solid-tumor focus
- High unmet medical need
- Multiple development paths
hunTR and mbIL-15 platforms
Alaunos Therapeutics, Inc. is widening its mix beyond the TCR Library with hunTR and mbIL-15. hunTR targets human neoantigen T-cell receptors, while mbIL-15 is built to support solid tumor treatment, a space that represents about 90% of adult cancers. That gives Alaunos Therapeutics, Inc. 2 added programs, which lowers single-asset risk.
- hunTR: human neoantigen TCRs
- mbIL-15: solid tumor support
- Broader pipeline, less concentration risk
Alaunos’ 10-TCR Pipeline Spans 6 Cancers, With No Sales Yet
Alaunos Therapeutics, Inc. product mix is led by its TCR Library, a Phase I/II adoptive T-cell receptor platform with 10 TCRs across 6 solid-tumor types. It targets KRAS, TP53, and EGFR, with no approved product or sales yet. hunTR and mbIL-15 add 2 more pipeline assets and reduce single-asset risk.
| Metric | Data |
|---|---|
| Lead product | TCR Library |
| Clinical assets | 10 TCRs |
| Target cancers | 6 |
| Added programs | 2 |
| Sales | None |
What is included in the product
Detailed Word Document
Provides a concise, company-specific 4P analysis of Alaunos Therapeutics, Inc.’s product, pricing, place, and promotion strategy.
Editable Excel File
Condenses Alaunos Therapeutics’ 4Ps into a quick, decision-ready snapshot for fast strategic review.
Reference Sources
Provides a concise, traceable bibliography of primary industry reports, clinical trial databases, and regulatory filings to speed due diligence on Alaunos Therapeutics.
Place
Houston, Texas HQ
Alaunos Therapeutics is headquartered in Houston, Texas, which anchors its corporate and strategic base. The site supports management, business development, and partner coordination, so key decisions stay close to the company’s central operations. Houston’s metro area has more than 7 million people, giving the Company access to a deep talent and partner pool.
Clinical trial sites
Alaunos Therapeutics, Inc. uses clinical trial sites as its only real “place” channel, so patients get access through enrollment at oncology research centers rather than retail or hospital pharmacy sales. For a pre-commercial biotech with no commercial distribution network, this keeps reach narrow and limited to trial settings where investigators can administer investigational cell therapies.
MD Anderson partnership
Alaunos Therapeutics, Inc. works with The University of Texas MD Anderson Cancer Center, ranked No. 1 for cancer care in U.S. News & World Report 2025-26. This puts part of the work inside a top oncology research hub, which supports translational research and clinical development. It also links Alaunos to deep cancer trial infrastructure and patient access.
NCI agreements
Alaunos Therapeutics, Inc. uses National Cancer Institute agreements to widen its R&D reach beyond its own lab base. The company has both a patent license and an R&D agreement with NCI, which gives it access to federal research know-how and protected IP. This is a key non-commercial channel for scientific exchange and asset access.
- Patent access and shared research
- Links to federal cancer networks
- Supports IP and know-how flow
- Strengthens early-stage development
PGEN licensing agreement
Alaunos Therapeutics, Inc. keeps a licensing agreement with PGEN Therapeutics, Inc., which gives it access to outside technology and development rights. For a clinical-stage Company Name, that matters because it can source product candidates without building every asset from scratch. In its latest public filings, Alaunos reported $0 product revenue, so licensed programs remain central to its pipeline.
- Access to PGEN technology
- Supports external development rights
- Fits a clinical-stage model
- $0 product revenue reported
Alaunos’ Access Runs Through Clinical Trial Sites, Not Retail
Alaunos Therapeutics, Inc. has no retail or hospital distribution; its Place is clinical trial sites, so patient access runs through oncology research centers. Its Houston, Texas base supports management and partner coordination, while MD Anderson and NCI ties anchor research access. That fits a pre-commercial model with $0 product revenue reported.
| Place channel | Key data |
|---|---|
| Clinical trial sites | Only access route |
| Houston HQ | 7M+ metro area |
| Commercial revenue | $0 product revenue |
Preview the Actual Deliverable
Alaunos Therapeutics, Inc. Reference Sources
The preview shown here is the actual Alaunos Therapeutics, Inc. 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises.
This is the same ready-made, fully editable marketing mix analysis you'll download immediately after checkout, covering product, price, place, and promotion tailored to Alaunos.
You're viewing the exact, final version of the analysis—comprehensive, actionable, and ready for immediate use.
Promotion
SEC filings
Alaunos Therapeutics, Inc. promotes itself mainly through SEC filings, a standard channel for public biotechs with no product revenue. These reports spell out pipeline progress, risks, and corporate updates, and they also show the company’s cash position and losses as investors track dilution and runway. For a pre-revenue biotech, the filing cadence itself is part of the marketing mix.
Press releases
Alaunos Therapeutics, Inc. uses press releases to share trial updates, collaborations, and corporate actions, and that matters because a clinical-stage oncology company lives on news flow. These releases build awareness with investors and scientific stakeholders, while also reinforcing credibility around pipeline progress and study milestones. For a company with no marketed cancer product, each update can move attention faster than ads or broad brand campaigns.
Scientific collaborations
Alaunos Therapeutics, Inc. uses 3 scientific collaborations—MD Anderson, NCI, and PGEN—as promotion by third-party validation, not just advertising. These names signal that outside institutions see enough value in the platform to work with it. In biotech, that kind of partner support often matters more than paid brand spend.
Clinical trial visibility
Phase I/II trial activity is Alaunos Therapeutics, Inc.’s main promotion engine because it generates clinical evidence before any saleable product. In biotech, each enrolled patient, data readout, and safety update can be shared publicly, which raises visibility with physicians, investigators, and patients.
That matters because early-stage trial milestones are the proof points investors and partners track; for a small-cap biotech with no commercial revenue, clinical progress is the message. The company can use enrollment, dose-escalation, and readout updates to keep attention on its pipeline and support trial recruitment.
- Phase I/II trials create public milestones.
- Clinical updates raise physician awareness.
- Enrollment helps attract investigators and patients.
- Promotion is evidence-led, not ad-led.
Former ZIOPHARM name change
Alaunos Therapeutics adopted its current name in January 2022, replacing ZIOPHARM to signal a new strategic identity and reset how the market views the business. For promotion, the name change supports repositioning with investors and partners by tying the brand to its cell-therapy focus. It is a simple corporate messaging move, but it helps separate the new story from the former ZIOPHARM legacy.
- January 2022 rebrand
- Signals strategic repositioning
- Supports investor messaging
- Part of corporate promotion
Alaunos Sells the Story Through Trials, Not Ads
Alaunos Therapeutics, Inc. promotes through SEC filings, press releases, and trial milestones, not paid ads. With no product revenue, its main message is pipeline progress, cash runway, and study updates. Third-party ties with MD Anderson, NCI, and PGEN add credibility, and the January 2022 name change helped reset the market story.
| Promotion channel | Key data |
|---|---|
| SEC filings | Ongoing public disclosure |
| Press releases | Trial, collaboration, and corporate updates |
| Scientific partners | MD Anderson, NCI, PGEN |
| Rebrand | Name changed in January 2022 |
Price
No marketed product price
Alaunos Therapeutics, Inc. had 0 approved commercial products as of July 2026, so there is no public customer price for any therapy. Any future pricing will depend on FDA approval, payer coverage, and reimbursement terms. For now, the market measures value through clinical milestones and pipeline progress, not list price.
Trial-stage economics
Alaunos Therapeutics, Inc. has no product sales, so its price story is tied to research funding and trial spend, not end-user pricing. In the latest filing cycle, the Company reported $0 product revenue, which is normal for a clinical-stage biotech and shows why capital raises fund operations. This makes the business model investment dependent, with pricing shaped by financing needs and dilution risk.
Licensing terms
Alaunos Therapeutics, Inc. faces price exposure mainly through licensing terms, not consumer pricing. In biotech deals, access to outside technology is often paid with upfront fees, milestone payments, and sometimes royalties, so the cash cost depends on the contract. For a development-stage company, this can directly affect burn rate and future dilution.
Future reimbursement unknown
Alaunos Therapeutics, Inc. has no approved oncology product, so future reimbursement and net price are still unknown. If a therapy reaches market, payers will likely demand clear clinical benefit, since high-value cancer drugs often need strong outcomes data to win coverage and support premium pricing.
Reimbursement will be a key driver of any eventual net price, but that stage has not been reached yet.
- No approved product, no set reimbursement
- Payer acceptance will shape net price
- Strong outcomes data will matter most
- Commercial pricing remains unpriced risk
No discount or retail model
Alaunos Therapeutics, Inc. has no retail discounting, subscriptions, or direct-to-consumer price list because its cell therapies are investigational and only supplied in clinical trials. There is no commercial price architecture yet, so pricing becomes relevant only after FDA approval and launch. Its latest public filings show it is still in a development stage, not a sales stage.
- Trial-only supply, no retail pricing
- No discounts or subscriptions
- Price model waits for approval
Alaunos Has No Approved Product, So Pricing Remains Unset
Alaunos Therapeutics, Inc. still has no approved product as of FY2026, so there is no commercial price or reimbursement rate to measure. In FY2025/FY2026 filings, product revenue stayed at $0, which means price is still an R&D and financing issue, not a sales issue. Any future net price will depend on FDA approval, payer coverage, and trial data.
| Price factor | FY2025/FY2026 |
|---|---|
| Product revenue | $0 |
| Approved commercial products | 0 |
| Current pricing status | Not set |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.